0000000000154775

AUTHOR

Milicic D

showing 3 related works from this author

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

2017

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

0301 basic medicine030204 cardiovascular system & hematologylaw.invention0302 clinical medicinec-reactive proteinRandomized controlled triallawCardiovascular Diseasemiddle ageddouble-blind methodantibodiesMyocardial infarctionhumansStrokeinterleukin-1betabiologyAntibodies MonoclonaldrugGeneral MedicineLipidAged; anti-inflammatory agents; antibodies; monoclonal; antibodies; monoclonal; humanized; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship; drug; double-blind method; female; humans; incidence; infections; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; strokestrokeAnti-Inflammatory AgentagedEditorialfemalemyocardial infarctionAtherosclerosiMonoclonalsecondary preventionHumanmedicine.drugmedicine.medical_specialtymonoclonalNeutropeniaAntibodies Monoclonal HumanizedInfectionsPlaceboaged; anti-inflammatory agents; antibodies monoclonal; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship drug; double-blind method; female; humans; incidence; infection; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; stroke; medicine (all)anti-inflammatory agentsdose-response relationshiplipids03 medical and health sciencesmaleInternal medicinemedicineneutropeniamedicine (all)Dose-Response Relationship Drugbusiness.industryAntiinflammatory Therapy Canakinumab for Atherosclerotic DiseaseC-reactive proteinmedicine.diseaseinfectioncardiovascular diseasesSurgeryCanakinumab030104 developmental biologyincidencebiology.proteinatherosclerosisbusinessNew England journal of medicine
researchProduct

COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction

2022

ObjectiveThe initial data of the International Study on Acute Coronary Syndromes - ST Elevation Myocardial Infarction COVID-19 showed in Europe a remarkable reduction in primary percutaneous coronary intervention procedures and higher in-hospital mortality during the initial phase of the pandemic as compared with the prepandemic period. The aim of the current study was to provide the final results of the registry, subsequently extended outside Europe with a larger inclusion period (up to June 2020) and longer follow-up (up to 30 days).MethodsThis is a retrospective multicentre registry in 109 high-volume primary percutaneous coronary intervention (PPCI) centres from Europe, Latin America, S…

RegistrieMaleST Elevation Myocardial Infarction/diagnosisTime FactorsPercutaneousmedicine.medical_treatmentVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Coronary Artery DiseasePractice Patterns030204 cardiovascular system & hematologyRate ratioTime-to-Treatment/trendsCardiologists0302 clinical medicineRetrospective StudieHeart RateRisk FactorsPandemicST segmentRegistriesHospital Mortality030212 general & internal medicineMyocardial infarctionPractice Patterns Physicians'10. No inequalityPercutaneous Coronary Intervention/adverse effectsHospital Mortality/trendsCOVID-19; myocardial infarction; percutaneous coronary interventionIncidenceIncidence (epidemiology)*percutaneous coronary interventionMiddle Aged3. Good healthTreatment Outcomemyocardial infarctionCardiologyFemale*COVID-19Cardiology and Cardiovascular MedicineCardiologists/trendsHumanCOVID-19; myocardial infarction; percutaneous coronary intervention; Aged; Cardiologists; Female; Hospital Mortality; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Practice Patterns Physicians'; Registries; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Time-to-Treatment; Treatment Outcome; COVID-19medicine.medical_specialtyTime FactorCoronavirus disease 2019 (COVID-19)CardiologistRisk AssessmentTime-to-Treatment03 medical and health sciencesInternal medicinemedicineHumansAcute Coronary SyndromePandemicsRetrospective StudiesAgedPhysicians'SARS-CoV-2business.industryRisk FactorCOVID-19 myocardial infarction percutaneous coronary interventionpercutaneous coronary interventionPercutaneous coronary interventionCOVID-19*myocardial infarctionmedicine.diseasePractice Patterns Physicians'/trendsST Elevation Myocardial Infarctionbusiness
researchProduct

2016 European Guidelines on cardiovascular disease prevention in clinical practice The Sixth Joint Task Force of the European Society of Cardiology a…

2016

ABI : ankle–brachial (blood pressure) index ABPM : ambulatory blood pressure monitoring ACCORD : Action to Control Cardiovascular Risk in Diabetes ACE-I : angiotensin-converting enzyme inhibitor ACS : acute coronary syndromes ADVANCE : Action in Diabetes and Vascular disease: PreterAx

Cost-Benefit AnalysisGeneral Practice030204 cardiovascular system & hematologyGuidelineDiabete0302 clinical medicineHyperlipidemiaStakeholderMedicine030212 general & internal medicineMultiple Chronic ConditionsPractice Patterns Physicians'Societies MedicalRisk assessmenteducation.field_of_studyCardiac RehabilitationDiabetesRehabilitationSmokingPsychosocial factorAge FactorsLipidMiddle AgedPrimary carePedigreeEuropeCardiovascular DiseasesPsychosocial factorsHypertensionBlood pressureDiet HealthyRisk assessmentCardiology and Cardiovascular MedicineAdultDiagnostic Imagingmedicine.medical_specialtyAmbulatory blood pressurePopulationPopulationCardiologyHealthy lifestyleHyperlipidemiasHealth PromotionDiabetic angiopathyGuidelinesRisk Assessment03 medical and health sciencesSex FactorsDiabetes mellitusJournal ArticleHumansClinical settingsHealthy LifestyleIntensive care medicineeducationExerciseAntihypertensive AgentsNutritionAgedbusiness.industryVascular diseasePhysical activityPreventionmedicine.diseasebody regionsClinical settingBlood pressureRisk managementSocioeconomic FactorsSmoking CessationJoint Esc GuidelinesbusinessBiomarkersDiabetic Angiopathies
researchProduct